ESMO Open, Journal Year: 2024, Volume and Issue: 9(1), P. 102205 - 102205

Published: Jan. 1, 2024

Over the past few decades, multiple studies have tried to stratify cancer survivors according their individual risk of treatment-related toxicities, particularly persistent 'sequelae' and deterioration health-related quality life.1Hertz D.L. Lustberg M.B. Sonis S. Evolution predictive factor analysis for chemotherapy-related toxicity.Support Care Cancer. 2023; 31: 601Crossref Scopus (0) Google Scholar Nevertheless, a substantial part contributors this inter-individual variability remains elusive. Seemingly similar patients may follow very different long-term patterns in terms subjective toxicity same—or closely related—classes drugs or treatment protocols.2Di Meglio A. Havas J. Gbenou A.S. et al.Dynamics patient-reported life health behaviors after adjuvant breast chemotherapy.J Clin Oncol. 2022; 40: 3190-3204Crossref PubMed (15) Scholar, 3Vaz-Luis I. Di al.Long-term longitudinal fatigue cancer: group-based trajectory analysis.J 2148-2162Crossref (14) 4Charles C. Bardet Larive al.Characterization depressive symptoms trajectories diagnosis women France.JAMA Netw Open. 5: E225118Crossref (8) This observation has catalyzed need improve ability accurately define predictors cancer-related frailty at level, personalize care pathways accordingly, from moment is made. Such model would allow implementation early, tailored management interventions as well preventive proactive supportive strategies that could reduce morbidity optimize utilization resources. Particularly, identification clinically actionable biomarkers symptom burden crucial intercept optimized patient stratification with delivery adapted interventions, thus successfully move forward field 'precision survivorship medicine'.5Hertz McShane L.M. Hayes D.F. Defining clinical utility germline indicators risk: perspective.J 1721-1731Crossref (6) Scholar,6Hayes tumor biomarker tests: clinician's viewpoint.J 2021; 39: 238-248Crossref (36) Refined knowledge physiological biology allowed unravel several mechanistic underlie enhanced certain individuals along trajectory,7Carroll J.E. Bower Ganz P.A. Cancer-related accelerated ageing biobehavioural modifiers: framework research care.Nat Rev 19: 173-187Crossref (20) identify some its factors, leveraging holistic connection between biology, psychology, behaviors, other socio-environmental mediators.8Sleight A.G. Crowder S.L. Skarbinski al.A new approach understanding fatigue: 3P facilitate prediction care.Cancers (Basel). 14: 1982Crossref Among biological factors been consistently proposed linked increased susceptibility long-lasting particular empirical attention given cancer-induced systemic inflammation, and, larger extent, related mechanisms aging, cellular damage, stress.7Carroll The accumulating evidence such act physiopathological heterogeneity among set out rationale study key pathway components delve deeper into molecular underpinnings, order discover potential drive personalized care. Basic focused on neural-immune signaling suggested stimulation central nervous system through release pool circulating cytokines activation proinflammatory axis herald appearance physical, emotional, cognitive manifestations, more broadly, number inflammation-related 'sickness behaviors'.9Bower role neuro-immune interactions biobehavioral mechanisms.Cancer. 2019; 125: 353-364Crossref (104) 10Dantzer R. O'Connor J.C. Freund G.G. al.From inflammation sickness depression: when immune subjugates brain.Nat Neurosci. 2008; 9: 46-56Crossref (5179) 11Collado-Hidalgo al.Inflammatory survivors.Clin Cancer Res. 2006; 12: 2759-2766Crossref (320) 12Bower fatigue--mechanisms, treatments.Nat 2014; 11: 597-609Crossref (900) Several studies, mostly cancer, described wide range stem common inflammatory substrate. For example, fatigue, decline, sleep disturbance, emotional distress, chronic pain are constellation usually concurrent 'behavioral' highly prevalent distressful survivors, which mutual etiology proposed, although lot granularity still needs be elucidated.10Dantzer Scholar,13Palesh O.G. Roscoe J.A. Mustian K.M. al.Prevalence, demographics, psychological associations disruption University Rochester Center-Community Clinical Oncology Program.J 2010; 28: 292-298Crossref (374) 14Lee B.N. Dantzer Langley K.E. cytokine-based neuroimmunologic mechanism symptoms.Neuroimmunomodulation. 2004; 279-292Crossref (235) 15Miller A.H. Ancoli-Israel al.Neuroendocrine-immune behavioral comorbidities cancer.J 26: 971Crossref (459) Along same lines, data available showing administration induction leads symptomatology also healthy humans16Reichenberg Yirmiya Schuld al.Cytokine-associated disturbances humans.Arch Gen Psychiatry. 2001; 58: 445-452Crossref 17Späth-Schwalbe E. Hansen K. Schmidt F. al.Acute effects recombinant human interleukin-6 endocrine functions men.J Endocrinol Metab. 1998; 83: 1573-1579Crossref (362) 18Eisenberger N.I. Inagaki T.K. Mashal N.M. al.Inflammation social experience: an challenge induces feelings disconnection addition depressed mood.Brain Behav Immun. 24: 558-563Crossref (298) elevated detected non-cancer populations distress syndromes.19Howren Lamkin D.M. Suls Associations depression C-reactive protein, IL-1, IL-6: meta-analysis.Psychosom Med. 2009; 71: 171-186Crossref (2210) Scholar,20Irwin M. Effects loss immunity cytokines.Brain 2002; 16: 503-512Crossref (293) However, seems prolonged severe compared without history suggesting precipitating treatments (particularly chemo-, radiation-, hormone-, immunotherapy targeted agents), potentially triggering hyperactivated cross-signaling feedforwarding cascades.12Bower Mounting pointed accelerator aging sustained damage While accumulation impairments interfering day-to-day function, deficit, increasing reduced physical performance, typical normative leading state elderly irrespective many report decline earlier onset greater likelihood becoming chronic, detriment life.21Guida J.L. Ahles T.A. Belsky D. al.Measuring identifying phenotypes survivors.J Natl Inst. 111: 1245-1254Crossref 22Searle S.D. Mitnitski Gahbauer E.A. standard procedure creating index.BMC Geriatr. 8: 1-10Crossref (2046) 23Fried L.P. Tangen C.M. Walston al.Frailty older adults: phenotype.J Gerontol A Biol Sci Med Sci. 56: M146-M156Crossref 24Henderson T.O. Ness K.K. Cohen H.J. Accelerated survivors: pediatrics geriatrics.Am Soc Oncol Educ Book. : e423-e430Crossref (103) Pre-existing, predisposing including age diagnosis, comorbid conditions, baseline psychosocial traits, coupled precipitating, perpetuating unhealthy lifestyles, favor cells enriched inflammation- stress mediators-biased 'secretome'.12Bower Scholar,15Miller Scholar,25Campisi Senescent cells, suppression, organismal aging: good citizens, bad neighbors.Cell. 2005; 120: 513-522Abstract Full Text PDF (1874) Scholar,26Van Waart H. Stuiver M.M. Van Harten W.H. al.Effect low-intensity activity moderate- high-intensity exercise during chemotherapy fitness, completion rates: results PACES randomized trial.J 2015; 33: 1918-1927Crossref (406) brought highlight specific markers inflammation. cytokines,27Bower Irwin M.R. al.Cytokine genetic variations 2013; 1656-1661Crossref (102) 28Collado-Hidalgo gene polymorphisms early findings.Brain 22: 1197-1200Crossref (110) 29Barsevick Frost Zwinderman Hall P. Halyard I'm so tired: fatigue.Qual Life 1419-1427Crossref 30Maurer T. Jaskulski Behrens al.Tired feeling tired – survivors.Breast. 103-109Abstract 31Shi W. Misra Li biomarkers, hematopoietic undergoing radiation therapy.JNCI Spectr. 2020; 4pkaa037Google 32Cohen Levkovich Katz al.Low activity, moderation by levels IL-6 IL-8158.Int J Psychophysiol. 158: 96-102Crossref 33Hiensch A.E. Mijwel Bargiela mediates cancer.Med Sports Exerc. 53: 496-504Crossref (27) 34Henneghan Wright M.L. Bourne G. cross-sectional exploration cytokine-symptom networks using network analysis.Can Nurs 303-315Crossref 35Cohen R.A. Gullett J.M. Woods A.J. prior to, during, post-chemotherapy Neuroimmunol. 334577001Abstract 36Toh Y.L. Tan C.J. Yeo A.H.L. al.Association plasma leptin, pro-inflammatory adipokines early-stage patients: prospective cohort study.J Cell Mol 23: 4281-4289Crossref 37Witek Janusek L. Tell Mathews H.L. Mindfulness based reduction provides benefit restores function newly diagnosed trial active control.Brain 80: 358-373Crossref (65) 38Lengacher C.A. Reich R.R. Paterson C.L. large trial: mindfulness-based (MBSR) (BC) salivary cortisol IL-6.Biol Res Nurs. 21: 39-49Crossref 39Chae J.W. Chua P.S. Ng mitochondrial DNA content peripheral blood impairment study.Breast Treat. 2018; 168: 713-721Crossref 40van Vulpen J.K. M.E. Velthuis M.J. al.Effects chemotherapy.Breast 421-431Crossref (22) 41Serra M.C. Ryan Ortmeyer H.K. al.Resistance training reduces improves survivors.Menopause. 25: 211Crossref 42Zimmer Baumann F.T. Oberste al.Influence recommendations rehabilitation sustainability objectively measured levels, fatigue-related cancer.Integr Ther. 17: 306Crossref (17) 43Xiao Miller Felger al.Depressive independent survivors.Psychol 2017; 47: 1733-1743Crossref (46) 44Zick S.M. Zwickey Wood al.Preliminary differences brain metabolites fatigued non-fatigued pilot study.Brain Imaging Behav. 506Crossref (23) 45Pertl Hevey Boyle N.T. al.C-reactive protein predicts independently chemotherapy.Brain 34: 108-119Crossref (68) 46Liu Mills P.J. Rissling al.Fatigue associated changes 2012; 706Crossref (163) 47Bower treatment: do depression, disturbance share underlying mechanism?.J 2011; 29: 3517Crossref (385) 48Bower Tao therapy prostate cancer.Clin 15: 5534-5540Crossref (251) 49Von Ah Kang D.H. Carpenter J.S. Predictors before, therapy.Cancer 134-144Crossref (52) 50Bower Aziz N. responses relationship glucocorticoids.Brain 2007; 251-258Crossref (129) 51Mills Parker B. Dimsdale al.The anthracycline-based cancer.Biol Psychol. 69: 85-96Crossref (93) 52Geinitz Zimmermann F.B. Stoll al.Fatigue, serum cytokine cell counts radiotherapy cancer.Int Radiat Phys. 51: 691-698Abstract (149) 53Rogers L.Q. Vicari Trammell al.Biobehavioral mediate survivors.Med 46: 1077-1088Crossref (51) interleukin (IL)-1b, IL-6, necrosis factor-alpha (TNF-a), seem implications orchestrating local spectrum host-defense energy mood.11Collado-Hidalgo Scholar,44Zick Scholar,53Rogers 54Bower patients.JNCI 6pkac052Google 55Raudonis B.M. Kelley I.H. Rowe chemotherapy.Cancer 323-331Crossref 56Minton O. Coulton G.R. Stone Multi-analyte profiling proteins syndrome disease-free primary treatment.BMJ Support Palliat Care. 4: 349-356Crossref these mediators higher across disease continuum, before surgery throughout treatments.11Collado-Hidalgo Scholar,57Bower survivors.Psychosom 64: 604-611Crossref Scholar,58Bower Asher Garet al.Testing cancer.Cancer. 633-641Crossref Downstream products play relevant response can contribute frailty. these, (CRP) acute-phase synthesized hepatocytes infectious processes marker diseases cardiovascular risk.59Furman Campisi Verdin al.Chronic span.Nature 1822-1832Crossref 60Carroll Nakamura Z.M. Small B.J. al.Elevated subsequent problems thinking living 41: 295-306Crossref (10) 61Pradhan A.D. Manson Rifai 6, developing type 2 diabetes mellitus.J Am Assoc. 286: 327-334Crossref Higher CRP meaning, (>3 mg/l) survivors.60Carroll Furthermore, variants toxicities shed optimism possibility acquired models characteristics.5Hertz instance, setting often take form single-nucleotide promoter region genes implicated oxidative behavioral-like symptoms.19Howren Scholar,27Bower Scholar,28Collado-Hidalgo Scholar,62Miaskowski Dodd Lee association functional IL6 polymorphism oncology family caregivers.J Pain Symptom Manage. 531Abstract 63Jim H.S.L. Park J.Y. Permuth-Wey al.Genetic treated androgen deprivation therapy: preliminary 1030-1036Crossref (32) 64Doong S.H. Dhruva Dunn L.B. al.Associations cluster pain, surgery.Biol 237-247Crossref (117) 65Bull S.J. Huezo-Diaz Binder E.B. al.Functional serotonin transporter genes, induced interferon-alpha ribavirin treatment.Mol 1095-1104Crossref (196) 66Musselman Porter al.Higher than normal concentrations findings.Am 1252-1257Crossref (387) 67Elderkin-Thompson V. Hellemann al.Interleukin-6 memory encoding recall adults.Am Geriatr 20: 753-763Abstract Additional polymorphisms, them stress, predisposition contributing cardiomyopathy following chemotherapy,68Kim Y. Seidman J.G. C.E. Genetics therapy-associated cardiotoxicity.J Cardiol. 167: 85-91Abstract Scholar,69Wang X. Sun Quiñones-Lombraña al.CELF4 variant anthracycline-related cardiomyopathy: children's group genome-wide 2016; 863-870Crossref oxaliplatin-associated neurotoxicity.70Sereno Gutiérrez-Gutiérrez Rubio SCN9A oxaliplatin-induced neuropathy.BMC 63Crossref How it then possible leverage link inform practice burden? Some aforementioned easily detectable if adequately incorporated screening tools build factors.71Di Soldato al.Development validation diagnosis: toward care.J 1111-1123Crossref (19) Novel technologies continuous monitoring 'dynamic biomarker', aiming anticipating symptoms.72Jagannath Lin K.C. Pali Sankhala Muthukumar Prasad sweat-based wearable enabling technology real-time IL-1β bowel disease.Inflamm Bowel Dis. 1533-1542Crossref (13) Scholar,73Laliberte Scott Khan Mahmud M.S. Song graphene transistor-based biosensor biomarker.Microelectron Eng. 262111835Crossref (7) cascade complex, was proxy low-grade status, therefore useful detection, monitoring, cancer- conditions.74Liu Zhang Q. all types: study.Int 151: 297-307Crossref Scholar,75Orsolini Pompili Tempia Valenta Salvi Volpe U. major disorder?.Int 1616Crossref (29) Understanding behind pave way development novel therapeutic target prevent symptomatic deterioration. With improved players cross-talk modifiers modulators identified. In setting, strong consistent traits. adiposity lower those who smokers, markers.12Bower Scholar,76Goodwin Stambolic Impact obesity epidemic cancer.Annu 66: 281-296Crossref (140) Similarly, bidirectional sarcopenia (i.e. skeletal muscle) neutrophil-to-lymphocyte ratio types.77Feliciano E.M.C. Kroenke C.H. Meyerhardt survival nonmetastatic colorectal

Language: Английский